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Collapsing glomerulopathy: Many 
means to a similar end
M Haas1
Collapsing glomerulopathy (CG) represents a morphologic pattern of 
disease, characterized histologically by glomerular capillary collapse, 
severe podocyte injury, and glomerular epithelial cell proliferation, 
and clinically by marked proteinuria and renal insufficiency. CG 
has multiple etiologies; however, many questions remain about its 
pathogenesis. A new set of animal models of CG, characterized by 
absence of the normal podocyte cytoskeletal protein α-actinin-4, has 
potential to help us gain a greater understanding of cellular events 
involved in producing this pattern of disease.
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Collapsing glomerulopathy (CG) is a 
relatively new form of glomerular dis-
ease; the ﬁrst cases of CG were reported 
in 1986,1 and retrospective reviews of 
renal biopsy archives from major cent-
ers in New York and Chicago identiﬁed 
their ﬁrst cases of CG in 1979 and 1980, 
respectively.2,3 CG has been classiﬁed 
as one of ﬁve morphologic variants of 
focal segmental glomerulosclerosis 
(FSGS) according to a recently proposed 
pathologic classiﬁcation for FSGS.4 Still, 
the relationship between CG and the 
other variants of FSGS remains rela-
tively unclear, and a more recently pro-
posed taxonomy of glomerular diseases 
characterized by primary podocyte 
injury classiﬁes CG apart from FSGS.5 
Among the proposed FSGS variants,4 
CG is clearly the most aggressive with 
respect to severity of proteinuria and 
likelihood of progression to end-stage 
renal disease,6 although, as with the 
other variants, the prognosis of CG is 
markedly improved if a complete or 
even partial remission of proteinuria 
is attained, either with treatment or 
(rarely) spontaneously.7
The morphologic lesion of CG, with 
glomerular capillary collapse and pseu-
docrescent formation (Figure 1), may 
result from multiple etiologies; likewise, 
with other histologic subtypes of FSGS, 
there are diﬀerent etiologies that ulti-
mately lead to the same, or very similar, 
morphologic ﬁndings.5 Etiologies of CG, 
summarized in Figure 1, include genetic 
abnormalities and acquired causes, the 
latter including infectious agents (most 
notably and well documented, HIV-1) as 
well as physical and/or chemical stimuli. 
For a more exhaustive review of docu-
mented and putative causes of CG, and 
references for each of these, the reader is 
directed to two recent reviews.5,8
Mutations in ACTN4, the gene encod-
ing the actin filament cross-linking 
protein α-actinin-4, a component of 
the podocyte cytoskeleton, have been 
found to cause a familial, autosomal 
dominant form of FSGS in humans, 
albeit not CG.9 Henderson, Pollak, and 
co-workers10 (this issue) now provide a 
detailed pathologic characterization of 
three diﬀerent strains of transgenic mice 
with altered expression of α-actinin-4: 
(1) homozygous ACTN4 knockout (KO) 
mice completely lacking this protein, (2) 
mice homozygous for a mutant form of 
α-actinin-4 with a single amino acid 
substitution corresponding to a muta-
tion (K255E) associated with develop-
ment of FSGS in humans (KI mice), 
and (3) mice heterozygous for this same 
mutation (HET mice). KO mice, com-
pletely lacking α-actinin-4, developed 
glomerulosclerosis as well as a morpho-
logic lesions and a ‘dysregulated podo-
cyte phenotype’11 that closely resembled 
human CG. The dysregulated podocyte 
phenotype is characterized by loss of 
proteins (for example, synaptopodin, 
WT-1) associated with normal podocyte 
diﬀerentiation and increased expression 
of cell-proliferation markers (cyclin D1 
and Ki-67). KI mice, containing only 
mutant α-actinin-4 protein, developed 
predominantly glomerulosclerosis with 
small numbers of CG lesions. Interest-
ingly, HET mice, the genetically faithful 
model of familial FSGS associated with 
ACTN4 mutations, developed patchy 
podocyte foot process eﬀacement but 
no light microscopic lesions of CG or 
other FSGS variants.10 By contrast, a 
mouse strain developed by Michaud et 
al.12 expressing both normal α-actinin-
4 and the same mutant protein exhibited 
non-collapsing FSGS in some but not 
all animals.
The potential value of mouse models 
such as those reported by Henderson 
et al.10 is twofold: (1) understanding 
of the pathogenesis of the modeled 
disease, in this case CG, and (2) use in 
testing potential therapeutic approaches 
to this disease. To start, the models of 
both Henderson et al.10 and Michaud 
et al.12 provide some important patho-
genetic information regarding CG and 
non-collapsing FSGS. First, these appear 
to be somewhat related lesions, manifest 
by diﬀerent severities and/or types of 
podocyte injury. In the study by Hend-
erson et al.,10 KO mice completely lack-
ing α-actinin-4 developed severe disease 
with early onset, histologic lesions in 
most glomeruli, and large numbers of 
glomeruli showing lesions of CG. KI 
mice expressing only mutant α-actinin-
4 developed somewhat less severe dis-
ease, with later onset, fewer glomeruli 
with histologic lesions, and most of 
the latter glomeruli showing segmen-
tal sclerosis rather than characteristic 
CG lesions. Humans expressing both 
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normal and mutant α-actinin-4 develop 
non-collapsing FSGS with onset in early 
adulthood,9 and mice expressing both 
proteins likewise developed either non-
collapsing FSGS12 or just ultrastructural 
podocyte abnormalities,10 perhaps the 
precursor of segmental sclerosis to 
develop later in life.
Another interesting implication of 
the ﬁndings of Henderson et al.10 is that 
primary podocyte injury alone appears 
suﬃcient to cause, or at the very least 
set into motion the events required to 
produce, glomerular lesions of CG. 
The speciﬁc role of the podocyte in the 
pathogenesis of CG has recently come 
into question. Early immunohistochem-
ical and ultrastructural studies suggested 
that CG was a primary podocyte disease, 
and that the abnormal swollen and pro-
liferating cells within Bowman’s space 
that are characteristic of CG are dys-
regulated, dediﬀerentiated podocytes.11 
However, recent immunohistochemical 
studies in idiopathic, HIV-associated, 
and pamidronate-associated CG have 
shown that these cells express proteins 
characteristic of the parietal epithelial 
cells lining Bowman’s capsule, and are 
segmentally in continuity with the cap-
sular epithelium.13,14 While one expla-
nation for these ﬁndings is that these 
cells are of parietal epithelial rather 
than podocyte origin,13,14 an alternative 
explanation5 is that the continuity of the 
cells with those lining Bowman’s capsule 
reﬂects the normal presence of parietal 
podocytes in human glomeruli,15 and 
that some dediﬀerentiated podocytes 
acquire markers of parietal epithelial 
cells, just as they also acquire mark-
ers of macrophage diﬀerentiation.16 A 
recent report17 that expression of nes-
tin, an intermediate ﬁlament protein 
showing podocyte-speciﬁc expression 
in mature glomeruli, persists within 
some cells forming the pseudocrescents 
of CG that lack other podocyte mark-
ers, would appear to lend some support 
to the latter hypothesis. The ﬁnding of 
Henderson et al.10 that loss of a func-
tional podocyte cytoskeletal protein can 
produce CG, together with earlier ﬁnd-
ings that podocyte-speciﬁc expression 
of HIV-1 genes in a susceptible strain 
of mice is suﬃcient for development of 
CG,18 also favors this same hypothesis 
and at least implicates podocyte injury 
as the initiating event in the pathogen-
esis of CG.
Finally, might this mouse model of CG 
be useful in testing potential therapeutic 
approaches to human CG? At ﬁrst the 
answer to this question might appear to 
be no, as human disease associated with 
mutations in ACTN4 has the morphol-
ogy of non-collapsing FSGS, and ACTN4 
mutations appear to account for only 
about 4% of familial human FSGS.19 
However, given the etiologic hetero-
geneity of CG, successful strategies to 
treat this condition will probably be 
aimed at events in its pathogenesis that 
are downstream from the initial molecu-
lar event and common to all or at least 
many forms of CG, such as aberrant pro-
liferation of renal epithelial cells. In this 
regard, Gherardi et al.20 tested the eﬀect 
of the cyclin-dependent kinase inhibi-
tor CYC202 on a mouse model of HIV-
associated CG (Tg26). They found that 8 
of 12 mice treated with CYC202 showed 
a decrease in proteinuria after treat-
ment, whereas proteinuria continued to 
increase in 10 of 12 vehicle-treated con-
trol mice. CYC202-treated mice also had 
less severe histologic lesions than control 
mice, with 33% of the treated group and 
none of the control group having a com-
plete absence of histologic lesions 20 
days after drug (or vehicle) administra-
tion.20 In a study of murine podocytes 
transfected in vitro with a portion of the 
HIV-1 genome,21 treatment of the cells 
with all-trans retinoic acid reversed 
the effects of the HIV-1 transfection, 
reducing the cells’ proliferation rate and 
restoring the expression of the diﬀeren-
tiation markers synaptopodin, nephrin, 
podocin, and WT-1. This eﬀect of all-
trans retinoic acid was mediated through 
the cyclic adenosine monophosphate–
protein kinase A pathway.21 Destabili-
zation of the podocyte cytoskeleton is 
another common feature of different 
forms of CG,8,22 and testing of therapeu-
tic interventions aimed at stabilizing this 
cytoskeleton might be another potential 
use of mouse models.
Pathologists have historically classi-
ﬁed diseases primarily on the basis of 
two-dimensional morphology. Although 
this has certainly proven useful in many 
regards, there are clear limitations to 
this two-dimensional approach, as evi-
denced by the many diﬀerent pathways 
that can lead to histologic lesions of 
FSGS, and even CG. Through the use of 
Figure 1 | Multiple etiologies of collapsing glomerulopathy. Collapsing glomerulopathy 
(CG; center photomicrograph) is characterized by collapse of the glomerular tuft with swollen, 
hyperplastic epithelial cells (podocytes and/or parietal epithelial cells; see text for additional 
details) forming a ‘pseudocrescent.’  These changes may be global, as shown here, or segmental. 
The summary of potential causes of CG shown here is not intended to be fully complete; for a more 
exhaustive list of documented and putative etiologies of CG, with references for each, refer to Table 
2 of Albaqumi et al.8 (Photomicrograph: silver methenamine stain; original magnification, ×400.)
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faithful animal models of human disease 
that are now becoming available through 
the application of molecular biological 
techniques, we can more closely exam-
ine these diﬀerent pathways and where 
they ultimately converge to yield a com-
mon morphologic picture, and in doing 
so add a new dimension to the study of 
glomerular and other diseases.
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It’s not all about nephrin
M Simons1 and TB Huber2
Mutations in the NPHS1 gene cause congenital nephrotic syndrome 
of the Finnish type.  The gene product nephrin is a structural 
component of the glomerular slit diaphragm formed by neighboring 
podocytes. Nephrin has also been suggested to  be involved in 
signaling processes that are important for podocyte survival and 
differentiation. A new study by Doné et al. reports that the absence 
of nephrin leads to the lack of slit diaphragms but does not affect 
podocyte apoptosis and gene expression patterns. 
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Ultraﬁltration of plasma in the renal 
glomeruli is a major function of the 
kidneys. During an average human life-
time, the glomeruli produce as much as 
5 million liters of primary urine. As the 
primary urine is virtually protein free, 
this means that more than 200,000 kg of 
albumin has to be prevented from cross-
ing the glomerular filtration barrier. 
The glomerular filter accomplishing 
this tremendous ﬁltration comprises a 
fenestrated endothelium, the glomeru-
lar basement membrane, and podocytes, 
highly specialized epithelial cells of the 
kidney. These podocytes elaborate long, 
regularly spaced, interdigitated foot 
processes that completely surround 
the glomerular capillaries and form an 
approximately 40-nm-wide ﬁltration 
slit. The ﬁltration slit is bridged by an 
electron-dense membrane-like struc-
ture, the slit diaphragm (Figures 1–3).
The molecular identity of the slit dia-
phragm remained elusive for decades 
until the Tryggvason group identified 
nephrin as a critical component of the 
slit membrane.1 Nephrin was discov-
ered through positional cloning of the 
NPHS1 gene, mutated in patients with 
congenital nephrotic syndrome of the 
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